newsfilter
← Latest News
GlobeNewswire·

Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for